Pulse Biosciences reports FY2023 net loss of $42.2M; plans $60M rights offering

PULSE BIOSCIENCES, INC.

GAAP net loss FY 2023 ($42.2M) vs ($58.5M) in 2022; Q4 net loss ($11.9M) vs ($9.2M) prior year.
Cash and equivalents $44.4M at Dec 31, 2023, down from $61.1M a year earlier.
FDA 510(k) clearance for CellFX nsPFA Percutaneous Electrode for non-cardiac soft tissue ablation.
Rights offering of up to $60M in Units (share + warrants) to existing holders; record date in April.
Chairman Robert Duggan supports and intends to participate in rights offering on same terms.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PULSE BIOSCIENCES, INC. reported the fiscal quarter and full year ended December 31, 2023 results: net income ($11.9) million.

Period: the fiscal quarter and full year ended December 31, 2023
Net income: ($11.9) million
Result: reported results

Exact text from the filing

On March 28, 2024, Pulse Biosciences, Inc. (the “Company”) announced its financial and operational results for the fiscal quarter and full year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

PULSE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-009831

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.